Literature DB >> 12529655

Molecular determinants of glucocorticoid sensitivity and resistance in acute lymphoblastic leukemia.

W J E Tissing1, J P P Meijerink, M L den Boer, R Pieters.   

Abstract

Glucocorticoids (GC) are probably the most important drugs in the treatment of ALL. Despite the extensive use of GC for many years, little is known about the molecular mechanisms of sensitivity and resistance. This review summarizes the knowledge on GC cytotoxicity in leukemia. The relevance of polymorphisms, splice variants and the number and regulation of the GC receptor are discussed. The role of multidrug resistance proteins, glutathione and glutathione S-transferase is evaluated, as well as the influence of the different heat-shock chaperone (hsp 90 and 70) and co-chaperone proteins (BAG-1 and others) which form a complex together with the GC receptor. Finally, the transactivation and transrepression (via NF-kappa B and AP-1 binding) of a wide range of genes (like c-myc) which initiates the final apoptosis pathway are discussed and suggestions for future directions of research in ALL patients are given.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 12529655     DOI: 10.1038/sj.leu.2402733

Source DB:  PubMed          Journal:  Leukemia        ISSN: 0887-6924            Impact factor:   11.528


  56 in total

Review 1.  Molecular pharmacodynamics in childhood leukemia.

Authors:  R Pieters; M L den Boer
Journal:  Int J Hematol       Date:  2003-12       Impact factor: 2.490

Review 2.  miRNAs in normal and malignant B cells.

Authors:  Ai Kotani; Ratanakanit Harnprasopwat; Takae Toyoshima; Toyotaka Kawamata; Arinobu Tojo
Journal:  Int J Hematol       Date:  2010-07-08       Impact factor: 2.490

3.  MAPK signaling cascades mediate distinct glucocorticoid resistance mechanisms in pediatric leukemia.

Authors:  Courtney L Jones; Christy M Gearheart; Susan Fosmire; Cristina Delgado-Martin; Nikki A Evensen; Karen Bride; Angela J Waanders; Faye Pais; Jinhua Wang; Teena Bhatla; Danielle S Bitterman; Simone R de Rijk; Wallace Bourgeois; Smita Dandekar; Eugene Park; Tamara M Burleson; Pillai Pallavi Madhusoodhan; David T Teachey; Elizabeth A Raetz; Michelle L Hermiston; Markus Müschen; Mignon L Loh; Stephen P Hunger; Jinghui Zhang; Michael J Garabedian; Christopher C Porter; William L Carroll
Journal:  Blood       Date:  2015-08-31       Impact factor: 22.113

4.  Glucocorticoid receptor knock down reveals a similar apoptotic threshold but differing gene regulation patterns in T-cell and pre-B-cell acute lymphoblastic leukemia.

Authors:  Jason R Schwartz; Purvaba J Sarvaiya; Wayne V Vedeckis
Journal:  Mol Cell Endocrinol       Date:  2010-02-17       Impact factor: 4.102

Review 5.  Cyclic nucleotide phosphodiesterases as targets for treatment of haematological malignancies.

Authors:  Adam Lerner; Paul M Epstein
Journal:  Biochem J       Date:  2006-01-01       Impact factor: 3.857

Review 6.  Glucocorticoid sensitivity in health and disease.

Authors:  Rogier A Quax; Laura Manenschijn; Jan W Koper; Johanna M Hazes; Steven W J Lamberts; Elisabeth F C van Rossum; Richard A Feelders
Journal:  Nat Rev Endocrinol       Date:  2013-10-01       Impact factor: 43.330

7.  Pharmacogenetics of outcome in children with acute lymphoblastic leukemia.

Authors:  Jose Claudio C Rocha; Cheng Cheng; Wei Liu; Shinji Kishi; Soma Das; Edwin H Cook; John T Sandlund; Jeffrey Rubnitz; Raul Ribeiro; Dario Campana; Ching-Hon Pui; William E Evans; Mary V Relling
Journal:  Blood       Date:  2005-02-15       Impact factor: 22.113

8.  miR-128b is a potent glucocorticoid sensitizer in MLL-AF4 acute lymphocytic leukemia cells and exerts cooperative effects with miR-221.

Authors:  Ai Kotani; Daon Ha; James Hsieh; Prakash K Rao; Diana Schotte; Monique L den Boer; Scott A Armstrong; Harvey F Lodish
Journal:  Blood       Date:  2009-09-11       Impact factor: 22.113

Review 9.  Steroid resistance in leukemia.

Authors:  Darshan S Shah; Raj Kumar
Journal:  World J Exp Med       Date:  2013-05-20

10.  MEK inhibitors potentiate dexamethasone lethality in acute lymphoblastic leukemia cells through the pro-apoptotic molecule BIM.

Authors:  A A Rambal; Z L G Panaguiton; L Kramer; S Grant; H Harada
Journal:  Leukemia       Date:  2009-04-30       Impact factor: 11.528

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.